HIGHTIDE Pipeline
HIGHTIDE integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation in both diseases.
Product | Proposed Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|
HTD1801 | NAFLD/NASH (Non-Alcoholic Fatty Liver Disease / Non-Alcoholic Steatohepatitis) | ![]() |
||||
PSC (Primary Sclerosing Cholangitis) | ![]() |
|||||
HTD4010 | Acute Pancreatitis | ![]() |
||||
HTD2802 | Inflammatory Bowel Disease (IBD) | ![]() |
New molecular entity: ionic salt of two active moieties
An innovative fixed dose combination of two known compounds with clear differentiation for unmet clinical needs
We will contact you as soon as possible
© 2020 HighTide Therapeutics Inc.